Workflow
INKON Life(300143)
icon
Search documents
盈康生命:盈康生命科技股份有限公司监事会关于2023年限制性股票激励计划首次授予部分第一个归属期归属名单的核查意见
2024-11-08 10:41
监事会关于 2023 年限制性股票激励计划首次授予部分 盈康生命科技股份有限公司 综上,监事会同意公司按照 2023 年限制性股票激励计划的相关规定办理对 171 名激励对象的 189.6247 万股限制性股票的归属事宜。本次归属事项符合相 关法律、法规及规范性文件所规定的条件,不存在损害公司及股东利益的情形。 盈康生命科技股份有限公司监事会 二○二四年十一月八日 1 第一个归属期归属名单的核查意见 根据《中华人民共和国公司法》(以下简称"《公司法》")《中华人民共 和国证券法》(以下简称"《证券法》")《上市公司股权激励管理办法》(以 下简称"《管理办法》")《深圳证券交易所创业板股票上市规则》(以下简称 "《上市规则》")《深圳证券交易所创业板上市公司自律监管指南第 1 号— —业务办理》等法律法规及《盈康生命科技股份有限公司 2023 年限制性股票激 励计划(草案)》《盈康生命科技股份有限公司章程》(以下简称"《公司章程》") 的规定,盈康生命科技股份有限公司(以下简称"公司")监事会对公司 2023 年 限制性股票激励计划首次授予部分第一个归属期符合归属条件的激励对象名单 进行了核实并发表核查意见如下 ...
盈康生命:2023年限制性股票激励计划首次授予部分第一个归属期归属条件成就的公告
2024-11-08 10:41
证券代码:300143 证券简称:盈康生命 公告编号:2024-068 盈康生命科技股份有限公司 关于公司 2023 年限制性股票激励计划首次授予部分第一个 归属期归属条件成就的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或者重大遗漏。 重要内容提示: 盈康生命科技股份有限公司(以下简称"盈康生命"或"公司")于2024年11月 8日召开第六届董事会第十二次(临时)会议,审议通过了《关于公司2023年限 制性股票激励计划首次授予部分第一个归属期归属条件成就的议案》,首次授予 部分符合归属条件的激励对象共计171人,可申请归属的限制性股票数量为 1,896,247股,占公司总股本的0.2953%。现将相关事项公告如下: 一、2023 年限制性股票激励计划简述 2023 年 9 月 12 日,公司召开 2023 年第三次临时股东大会,审议并通过了 《关于公司<2023 年限制性股票激励计划(草案)>及其摘要的议案》等相关议 案,公司 2023 年限制性股票激励计划的主要内容如下: 6、激励计划的有效期和归属安排情况: 1、股权激励方式:第二类限制性股票 2、标的股票种 ...
盈康生命:关于签订募集资金三方监管协议的公告
2024-11-04 08:37
证券代码:300143 证券简称:盈康生命 公告编号:2024-065 盈康生命科技股份有限公司 关于签订募集资金三方监管协议的公告 一、募集资金基本情况 经中国证券监督管理委员会(以下简称"中国证监会")《关于同意盈康生命 科技股份有限公司向特定对象发行股票注册的批复》(证监许可[2024]1065号)同 意,盈康生命科技股份有限公司(以下简称"盈康生命"或"公司")向特定对 象青岛盈康医疗投资有限公司发行人民币普通股(A股)股票107,897,664股,每 股面值为人民币1元,每股发行价格为人民币8.99元,募集资金总额为人民币 969,999,999.36元,扣除各项发行费用(不含税)人民币9,610,721.65元后,实际 募集资金净额为人民币960,389,277.71元。上述募集资金已于2024年10月18日全 部到账,和信会计师事务所(特殊普通合伙)对募集资金到位情况进行了审验, 并出具了《盈康生命科技股份有限公司向特定对象发行股票募集资金验资报告》 (和信验字(2024)第000033号)。 二、《募集资金三方监管协议》的签订情况和募集资金专户的开立情况 为规范公司募集资金的管理和使用,保护投 ...
盈康生命:2024年三季报点评:Q3业绩稳健增长,定增完成助力长期发展
EBSCN· 2024-10-30 09:19
Investment Rating - The report maintains a "Buy" rating for Yingkang Life [2][7]. Core Views - The company has shown steady growth in Q3 2024, with revenue reaching 404 million yuan, an increase of 6.55%, and a net profit of 28 million yuan, up 18.59% [1]. - The completion of a private placement by the major shareholder raised 960 million yuan, which will be used to enhance liquidity and support long-term development in both medical services and medical devices [2]. - The company is focusing on dual-driven growth in medical services and medical devices, with plans to improve service capabilities and expand product lines [2]. Summary by Sections Q3 Performance - In Q3 2024, the company achieved operating revenue of 404 million yuan (+6.55%) and a net profit of 28 million yuan (+18.59%) [1]. - The first three quarters of 2024 saw total revenue of 1.228 billion yuan (+11.26%), but net profit decreased to 83 million yuan (-12.24%) [4]. Financial Metrics - The sales expense ratio, management expense ratio, and R&D expense ratio for Q3 2024 were 3.12%, 9.22%, and 2.91%, respectively, showing a decline from the previous year [1]. - The projected net profits for 2024-2026 are estimated at 126 million yuan, 157 million yuan, and 195 million yuan, with corresponding EPS of 0.20, 0.24, and 0.30 yuan, and PE ratios of 53, 43, and 34 times [2]. Major Shareholder Activity - The major shareholder, Qingdao Yingkang Medical Investment Co., Ltd., fully subscribed to the private placement, which is expected to support the company's long-term growth in both medical services and medical devices [2].
盈康生命:Q3稳健增长,定增完成有望加速推进战略落地
China Post Securities· 2024-10-28 08:09
Investment Rating - The report maintains a "Buy" rating for the company [2][5] Core Insights - The company has shown steady growth in Q3 2024, with revenue and profit meeting expectations. The revenue for the first three quarters of 2024 reached 1.228 billion yuan, an increase of 11.26%, while the net profit attributable to shareholders was 83 million yuan, a decrease of 12.24% [2][3] - The completion of a private placement of shares is expected to enhance the company's financial strength and accelerate the implementation of its strategic initiatives [4][5] Financial Performance Summary - For Q3 2024, the company reported revenue of 404 million yuan, up 6.55%, and a net profit of 28 million yuan, up 18.59% [2][3] - The gross margin for the first three quarters of 2024 was 26.16%, down 3.62 percentage points, while the net profit margin was 6.72%, down 1.80 percentage points [3] - The company’s operating cash flow for the first three quarters was 247 million yuan, an increase of 34.10% [2] Future Earnings Forecast - The company aims to build a comprehensive ecosystem in the medical service and medical device sectors, focusing on oncology. Revenue projections for 2024 to 2026 are 1.695 billion, 2.038 billion, and 2.454 billion yuan, respectively, with net profits of 121 million, 161 million, and 216 million yuan [5][7] - The current price-to-earnings (P/E) ratios for the next three years are projected to be 53.7, 40.2, and 30.0 times [5][7] Shareholder Information - The largest shareholder is Qingdao Yinkang Medical Investment Co., Ltd., which fully subscribed to the recent private placement, acquiring 14.39% of the total shares post-issuance [4]
盈康生命:第六届董事会第十一次(临时)会议决议公告
2024-10-27 07:38
本次会议的通知、召集、召开和表决程序符合《中华人民共和国公司法》等有 关法律、行政法规、部门规章、规范性文件及《盈康生命科技股份有限公司公司章 程》的规定。 二、董事会会议审议情况 (一)审议通过《关于公司 2024 年第三季度报告的议案》 证券代码:300143 证券简称:盈康生命 公告编号:2024-061 盈康生命科技股份有限公司 第六届董事会第十一次(临时)会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 盈康生命科技股份有限公司(以下简称"公司")于 2024 年 10 月 22 日以电 话、邮件等方式向全体董事发出召开公司第六届董事会第十一次(临时)会议的通 知。会议于 2024 年 10 月 25 日在山东省青岛市崂山区海尔路一号盈康一生大厦 19 楼董事会议室以现场结合通讯的方式召开。会议应出席董事 7 人,实出席董事 7 人, 董事谭丽霞、彭文以现场方式出席会议并投票表决,董事潘绵顺、沈旭东、独立董 事杜媛、独立董事姜峰、独立董事陈晓满以通讯方式出席会议并投票表决。本次会 议由董事长谭丽霞女士主持,公司的监 ...
盈康生命(300143) - 2024 Q3 - 季度财报
2024-10-27 07:38
Financial Performance - The company's revenue for Q3 2024 reached ¥404,486,670.70, an increase of 6.55% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2024 was ¥27,743,517.26, representing an 18.59% increase year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥25,095,140.38, up by 6.05% from the previous year[3] - Basic earnings per share for Q3 2024 were ¥0.0438, an increase of 10.89% year-on-year[3] - The company experienced a decline in net profit for the year-to-date period, which was ¥82,544,665.51, down by 12.24% compared to the same period last year[3] - Total operating revenue for Q3 2024 reached ¥1,227,709,136.74, an increase of 11.3% compared to ¥1,103,414,216.68 in the same period last year[23] - The net loss for the period narrowed to ¥-1,430,950,762.77 from ¥-1,513,495,428.28 year-over-year[22] - Total comprehensive income for the third quarter was CNY 83,135,409.36, compared to CNY 90,478,258.54 in the same quarter last year, indicating a decrease of about 8.5%[24] Assets and Liabilities - The total assets at the end of Q3 2024 amounted to ¥2,580,708,659.43, reflecting a 7.52% increase from the end of the previous year[4] - Non-current assets totaled ¥1,642,127,669.40, an increase of 10.3% from ¥1,488,256,028.05 in the previous year[21] - Current liabilities increased to ¥796,916,880.80, up 5% from ¥759,382,954.68 in Q3 2023[21] - The company's total assets reached ¥2,580,708,659.43, a growth of 7.5% compared to ¥2,400,229,493.43 last year[22] - The total equity attributable to shareholders at the end of Q3 2024 was ¥1,424,238,141.12, an increase of 3.08% from the end of the previous year[4] - The total equity attributable to shareholders of the parent company increased to ¥1,424,238,141.12, up from ¥1,381,668,862.20 in the previous year[22] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥246,904,117.19, a significant increase of 34.10% compared to the same period last year[6] - Cash flow from operating activities increased to CNY 1,309,639,348.87, compared to CNY 1,165,903,343.12 in the previous year, marking a growth of about 12.3%[25] - The company reported a net cash outflow from investing activities of CNY -424,002,098.11, worsening from CNY -279,796,919.97 in the prior year[26] - Cash and cash equivalents at the end of the period stood at CNY 351,334,329.97, down from CNY 369,994,096.48 at the end of the previous year[26] - The company's cash and cash equivalents decreased from RMB 480.49 million at the beginning of the period to RMB 355.54 million at the end of the period, representing a decline of approximately 26.1%[20] Shareholder Activities - The company received approval from the China Securities Regulatory Commission for a specific stock issuance on August 27, 2024, allowing it to raise funds through targeted offerings[11] - The controlling shareholder, Yingkang Medical Investment, increased its stake by acquiring 6,202,900 shares, representing 0.98% of the total share capital, with a total investment of approximately RMB 50 million[12] - The company approved a plan to use up to RMB 300 million of idle funds for cash management, focusing on low-risk, high-liquidity deposit products[13] - The company awarded 969,000 restricted stock units to 22 incentive targets at a price of RMB 5.08 per share on September 23, 2024, as part of its 2023 incentive plan[14] - The company has disclosed multiple announcements regarding stock issuance and shareholder activities, indicating ongoing strategic financial maneuvers[17] - The company has completed the share buyback plan by the controlling shareholder, indicating confidence in the company's future performance[19] Investments and Related Transactions - The company engaged in a related party transaction with a bid of RMB 8.298 million for a medical technology project, awarded to a subsidiary of the controlling shareholder, Haier Group[15] - The company plans to establish a new investment fund with a target total scale of RMB 300 million, with a total subscribed capital of RMB 137.5 million[16] - The company will contribute RMB 10 million as a limited partner in the new fund, while other partners will contribute varying amounts, including RMB 45 million and RMB 30 million from different entities[16] - The company is involved in related party transactions due to its investment partnerships, which are governed by regulations[16] Expenses - Total operating costs for Q3 2024 were ¥1,121,158,642.67, up 13.7% from ¥985,924,499.67 in Q3 2023[23] - Research and development expenses for Q3 2024 were ¥36,844,629.34, a decrease of 13.5% from ¥42,555,359.64 in Q3 2023[23] - The company incurred a total of CNY 54,739,085.80 in taxes paid, slightly down from CNY 59,769,170.06 in the same period last year[25] Other Financial Metrics - The weighted average return on equity for the year-to-date period was 5.93%, down by 1.14% compared to the same period last year[3] - The company reported a decrease in accounts payable to ¥231,900,141.74 from ¥169,437,299.16, reflecting a 37% increase year-over-year[21] - Accounts receivable decreased from RMB 254.45 million to RMB 228.27 million, a reduction of about 10.3%[20] - Inventory increased from RMB 87.79 million to RMB 95.28 million, reflecting an increase of approximately 8.5%[20] - Non-current assets include fixed assets valued at RMB 238.26 million, up from RMB 204.27 million, indicating a growth of about 16.6%[20] - The company reported a significant increase in other current assets from RMB 58.12 million to RMB 166.50 million, an increase of approximately 186.5%[20] - The company reported a decrease in other comprehensive income, with a net amount of CNY -64,371.68 compared to CNY -1,699,207.76 in the previous year[24] - Basic earnings per share decreased to CNY 0.1298 from CNY 0.1588, reflecting a decline of approximately 18.0%[24]
盈康生命:关于子公司与关联方签订合同暨关联交易的公告
2024-10-27 07:38
证券代码:300143 证券简称:盈康生命 公告编号:2024-064 盈康生命科技股份有限公司 关于子公司与关联方签订合同暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记 载、误导性陈述或重大遗漏。 盈康生命科技股份有限公司(以下简称"公司"或"盈康生命")于2024年10 月25日分别召开第六届董事会第十一次(临时)会议、第六届监事会第十次(临时) 会议,审议通过了《关于子公司与关联方签订合同暨关联交易的议案》,本议案无 需提交股东大会审议。现将相关事项公告如下: (三)本次交易的审批情况 公司于 2024 年 10 月 25 日召开第六届董事会第十一次(临时)会议,以 4 票 同意,0 票反对,0 票弃权审议通过了《关于子公司与关联方签订合同暨关联交易 的议案》,关联董事谭丽霞、彭文、沈旭东回避表决,独立董事已通过独立董事专 门会议对本议案发表了明确同意的审核意见。 1 公司于 2024 年 10 月 25 日召开第六届监事会第十次(临时)会议,以 2 票同 意,0 票反对,0 票弃权审议通过了《关于子公司与关联方签订合同暨关联交易的 议案》,关联监事龚雯雯回避表决 ...
盈康生命:第六届监事会第十次(临时)会议决议公告
2024-10-27 07:38
证券代码:300143 证券简称:盈康生命 公告编号:2024-062 盈康生命科技股份有限公司 第六届监事会第十次(临时)会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 盈康生命科技股份有限公司(以下简称"公司")于2024年10月22日以电话、邮 件方式向全体监事发出召开公司第六届监事会第十次(临时)会议的通知。本次会议 于2024年10月25日在山东省青岛市崂山区海尔路一号盈康一生大厦19楼董事会议室以 现场的方式召开。会议应出席3人,实出席3人,监事龚雯雯、王旭东、李超峰以现场 方式出席会议并投票表决。本次会议由监事会主席龚雯雯女士召集和主持,公司部分 高级管理人员列席了会议。 本次会议的通知、召集、召开和表决程序符合《中华人民共和国公司法》《公司 章程》及有关法律、行政法规、部门规章、规范性文件的规定。 二、监事会会议审议情况 (一)审议通过《关于公司 2024 年第三季度报告的议案》 公司监事会根据《中华人民共和国公司法》和《公司章程》的有关规定,本着对 全体股东负责的态度,谨慎履行法律、法规赋予的职责,审核了 ...
盈康生命:盈康生命科技股份有限公司向特定对象发行股票募集资金验资报告
2024-10-23 03:52
验资报告 和信验字(2024) 第 000033 号 目 录 页 码 一、验资报告 1-3 二、验资报告附件 1、新增注册资本实收情况明细表 4 2、注册资本及股本变更前后对照表 5 3、验资事项说明 6-9 TPH 和信会计师事务所 (特殊普通合伙) 二〇二四年十月十八日 盈康生命科技股份有限公司 盈康生命科技股份有限公司 向特定对象发行股票募集资金 107,897,664.00 元,计入资本公积人民币 852,491,613.71 元,投资者以货币出资。 和信验字(2024)第 000033 号 盈康生命科技股份有限公司: 我们接受委托,审验了盈康生命科技股份有限公司(以下简称"贵公司") 截至 2024年 10月 18 日止新增注册资本及股本情况。按照法律法规以及协议、 章程的要求出资,提供真实、合法、完整的验资资料,保护资产的安全、完整是 全体股东及贵公司的责任。我们的责任是对贵公司新增注册资本及股本情况发表 审验意见。我们的审验是依据《中国注册会计师审计准则第 1602 号 -- 验资》 进行的。在审验过程中,我们结合贵公司的实际情况,实施了检查等必要的审验 程序。 贵 公司 原 注 册 资 本 为 ...